C5G Stock Chart & Stats
€3.42
€0.02(1.49%)
At close: 4:00 PM EST
€3.42
€0.02(1.49%)
Day’s Range― - ―
52-Week Range€1.61 - €3.83
Previous CloseN/A
Volume0.00
Average Volume (3M)215.00
Market Cap
€75.40M
Enterprise Value€358.47M
Total Cash (Recent Filing)€386.20M
Total Debt (Recent Filing)€7.00M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Jul 16, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding35,127,056
10 Day Avg. Volume527
30 Day Avg. Volume215
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€2.35M
Bulls Say, Bears Say
Bulls Say
Cash GenerationA sustained swing to positive operating and free cash flow (~117M TTM) is a durable strength: it provides internal funding for R&D and commercialization, reduces dependency on external financing, and offers a buffer while management works to restore revenue and margins.
Low Leverage / Improved Balance SheetVery low current leverage and positive equity materially reduce financial risk and preserve strategic optionality. With minimal debt service pressure the company can support product launches, partnerships, or M&A without being constrained by near-term refinancing needs.
Specialty Pharma & Digital Therapeutics FocusA focused business model targeting specialty pharmaceuticals and digital therapeutics creates durable advantage: niche therapeutic focus (OUD) and digital offerings can yield higher margins, tighter clinical positioning, and diversified revenue streams via licensing and partnerships over time.
Bears Say
Steep Revenue ContractionA >50% TTM revenue decline is a structural concern: a shrinking sales base undermines scale economics, strains commercial investments, and increases per-unit costs. Recovery requires durable demand improvements or successful new product commercialization to restore profitability.
Persistently Negative ProfitabilityDeeply negative margins despite cash flow improvement indicate operating costs or one-time charges are overwhelming gross profit. Continued losses limit reinvestment capacity and make long-term viability dependent on sustained revenue recovery or ongoing external funding.
Historical Balance Sheet VolatilityPast episodes of high leverage and even negative equity signal structural volatility in capital structure. That history raises the risk of recurrence during future shocks and could increase cost of capital or constrain partnership and licensing opportunities if stakeholders doubt stability.
Orexo AB News
C5G FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was €1.61 and its highest was €3.83 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is €75.40M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 16, 2026 which is in 5 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -€0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.27.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.14.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -€0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.65%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in DE:C5G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
C5G Company Deck
C5G Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all DE:C5G earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---